Rx-360 Summary of the First Annual Report on Drug Shortages
On 5 February 2014, the FDA provided their First Annual Report on Drug Shortages to Congress as required by Section 1002 of FDASIA. FDA believes that the increased notifications resulting from action by the Administration, Congress and FDA has allowed them to respond more effectively to shortages and potential shortages. Pages 1–5 summarize the legal authority in this area and the guidances and actions FDA has taken so far to prevent and mitigate drug shortages.
FDA provides data on actions in this area, including but not limited to
• 39 different manufacturers notified FDA of 202 potential drug shortages.
• The Office of Generic Drugs (OGD) expedited review of 118 applications including 62 ANDAs and 56 supplements; the office of biological products expedited review of 7 supplements; in total CDER expedited review of 177 applications that includes ANDAs/NDAs and supplements in the first three quarters of calendar year 2013.
• 56 inspections were prioritized based on the applications/supplements that were granted expedited review.
• Figure 1 shows the number of new drug shortages annually between 2005 and Q1-3 of 2013. These increased to a high of 251 in 2011, decreased to 117 in 2012 and 38 for the first three quarters of 2013. They conclude that “…in the first three quarters of 2013, we have prevented 140 shortages.”
To view or download the Rx-360 Summary, click here
To view or download the FDA report, click here
Related News
-
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News US FDA grants priority review for Eisai and Biogen's Alzheimer's drug
Decision by US drug regulator on lecanemab expected by early next year -
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor... -
News Pharma Explained: What is Quality Risk Management & cGMPs?
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPHI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta... -
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations
Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPHI Festival of Pharma -
News Successful MHRA regulatory inspection for Scottish CMO Symbiosis
Inspection conducted remotely using video-conferencing and an online private document sharing platform.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance